

# Serum levels of copper and zinc in diabetic retinopathy: Potential new therapeutic targets (Review)

ANA MARIA DASCALU<sup>1,2</sup>, ANCA ANGHELACHE<sup>2</sup>, DANIELA STANA<sup>2</sup>, ANDREEA CRISTINA COSTEA<sup>3</sup>,  
VANESSA ANDRADA NICOLAE<sup>1,2</sup>, DENISA TANASESCU<sup>4</sup>, DANIEL OVIDIU COSTEA<sup>5,6</sup>,  
LAURA CARINA TRIBUS<sup>7,8\*</sup>, ANCA ZGURA<sup>9,10</sup>, DRAGOS SERBAN<sup>11,12</sup>, LUCIAN DUTA<sup>12</sup>, MIRUNA TUDOSIE<sup>13</sup>,  
SIMONA ANDREEA BALASESCU<sup>12</sup>, CIPRIAN TANASESCU<sup>14,15\*</sup> and MIHAIL SILVIU TUDOSIE<sup>16,17</sup>

<sup>1</sup>Department of Ophthalmology, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest;

<sup>2</sup>Department of Ophthalmology, Emergency University Hospital, 050098 Bucharest; <sup>3</sup>Department of Nephrology and Dialysis, 'Diaverum' Nephrology and Dialysis Clinic, 900612 Constanta; <sup>4</sup>Fourth Department of Dental Medicine and Nursing,

Faculty of Medicine, 'Lucian Blaga' University, 550169 Sibiu; <sup>5</sup>Department of Surgery, Faculty of Medicine, 'Ovidius' University, 900470 Constanta; <sup>6</sup>First Surgery Department, Emergency County Hospital, 900591 Constanta;

<sup>7</sup>Department of Internal Medicine, Ilfov County Emergency Hospital, 022104 Bucharest;

<sup>8</sup>Department of Internal Medicine, Faculty of Dental Medicine, 'Carol Davila' University of Medicine and Pharmacy;

<sup>9</sup>Department of Oncology, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest;

<sup>10</sup>Department of Oncology-Radiotherapy, Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', 022328 Bucharest;

<sup>11</sup>Department of General Surgery, Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy,

020021 Bucharest; <sup>12</sup>Fourth Department of Surgery, Emergency University Hospital, 050098 Bucharest;

<sup>13</sup>Department of Ophthalmology, 'Regina Maria' Polyclinic, 061077 Bucharest; <sup>14</sup>Department of Clinical Surgery,

Faculty of Medicine, 'Lucian Blaga' University, 550169 Sibiu; <sup>15</sup>Department of Surgery,

Sibiu County Clinical Emergency Hospital, 550245 Sibiu; <sup>16</sup>Department of Toxicology, Faculty of Medicine,

'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest;

<sup>17</sup>ICU II Toxicology, Clinical Emergency Hospital, 014461 Bucharest, Romania

Received November 8, 2021; Accepted December 8, 2021

DOI: 10.3892/etm.2022.11253

**Abstract.** Diabetic retinopathy (DR) is a microvascular disorder occurring due to the long-term effects of diabetes, leading to vision-threatening damage to the retina. The human body has an elaborate system for managing and regulating the number of key trace metals circulating in the blood and stored cells. Inadequate zinc (Zn) and concurrent excess of copper (Cu) levels are associated with an increased level of oxidative stress, which may aggravate the microvascular lesions in diabetes mellitus. Several studies have revealed a significantly lower serum Zn concentration and increased Cu

levels in DR when compared with diabetic patients without retinopathy and normal controls. These abnormalities are correlated with the duration of diabetes and higher levels of HbA1C. Multiple pathological mechanisms are proposed to explain these changes including hyperzincuria associated with polyuria, glycosuria, and proteinuria in diabetic patients, as well as impaired absorption of Zn at the gastrointestinal level. Increased levels of free Cu ions may be attributed to glycation and the release of Cu ions from the Cu-binding sites of proteins. Zn supplements and selective Cu chelators may be useful to alleviate oxidative stress and prevent DR progression.

*Correspondence to:* Dr Andreea Cristina Costea, Department of Nephrology and Dialysis, 'Diaverum' Nephrology and Dialysis Clinic, 20 Nicolae Iorga Street, 900612 Constanta, Romania  
E-mail: acostea2021@gmail.com

\*Contributed equally

**Key words:** trace elements, copper, zinc, diabetic retinopathy, oxidative stress, microcirculation, inflammation

## Contents

1. Introduction
2. Biological role of Zn in the retina
3. Zn metabolism disturbances in diabetes mellitus (DM)
4. Biological role of Cu in the retina and optic nerve
5. Cu metabolism disturbances in diabetic patients
6. Serum Cu and Zn levels in diabetic retinopathy (DR) vs. controls in clinical studies
7. Future therapeutic implications
8. Conclusions

## 1. Introduction

Diabetes mellitus (DM) is a global health problem that has seen an increasing incidence in the last three decades. According to a recent study by Liu *et al*, the overall incidence of DM increased by 102.9% between 1990 and 2017, with the majority (98.3%) of cases being type 2 DM (T2DM) (1). With a silent evolution for years, DM causes a tremendous burden on the health national systems, due to its microvascular and macrovascular complications (1,2).

The microvascular complications include neuropathy, nephropathy, and retinopathy, while the macrovascular complications are related to the acceleration of atherosclerosis, resulting in coronary artery disease, cerebrovascular events and peripheral arterial disease (3,4). Microvascular and macrovascular complications often occur concomitantly, sharing the same risk factors and involving similar pathological mechanisms. Duration of diabetes, poor glycemic control, increased blood pressure and altered lipid profile are independently associated with both microvascular and macrovascular damages (5).

Previous studies have revealed that T2DM is a chronic metabolic disorder associated with alterations in the status of trace elements, including zinc (Zn) and copper (Cu) (6-10). Homeostatic mechanisms maintain their concentration in the human body within a normal range (11). They play important catalytic, structural, and regulatory roles in proteins and enzymes of general cell metabolism, including gene expression, antioxidant defense systems, and mitochondrial processes (6,10,12). DM is associated with an increased level of free radicals and increased reactive oxygen species (ROS), as a consequence of the effect of chronic hyperglycemia in mitochondria and the endoplasmic reticulum (13).

DR may be the most common microvascular complication of diabetes and is considered the first cause of preventable blindness worldwide, with a profound effect on the quality of life (14,15). At a macroscopic level, obesity and a sedentary lifestyle are well-known risk factors for T2DM, but at a molecular level, oxidative stress is regarded as the primary contributor to the pathogenic processes leading to cellular and vascular damage (16). A high level of glycemia induces specific changes in the retinal microvasculature via the intracellular polyol pathway, increased oxidative stress, and accumulation of advanced glycation end-products (AGEs) (17). The retina is a tissue extremely metabolically active and is susceptible to variations in concentrations of these trace elements. As free ions, they participate in angiogenesis, nerve myelination, endorphin action, and synaptic transmission (18). The most abundant metal in the retina is Zn, followed by iron and Cu (19).

Clinically, DR can be classified as non-proliferative DR (NPDR) and proliferative DR (PDR). NPDR is characterized ophthalmoscopically by the presence of microaneurysm and dot-blot hemorrhages. Severe NPDR is characterized by cotton wool spots, venous beading, and loops, as well as intraretinal microvascular complications. If left untreated, PDR may occur with retinal neovascularization. Consequences of PDR are retinal and vitreous hemorrhage and tractional retinal detachment, which ultimately results in blindness. Despite the significant development of effective treatments, DR remains the leading cause of blindness (20).

Minerals play an important role in the progression of complications of DM, including DR. The metabolism of several minerals has been reported to be altered in DM. Among these minerals Zn and Cu are the most important (21).

The aim of the present review was to assess the data regarding the changes in serum Cu and Zn encountered in patients with DR, the mechanisms and pathological association, and the therapeutic strategies that may control the progression of DR associated with Cu-Zn imbalance. A comprehensive search was performed on PubMed and Google Scholar using the key words 'diabetic retinopathy' and 'Cu' or 'Zn'. All English articles for which full text was freely available were included in the review. After duplication removal a total of 70 articles were identified. Due to the limited available studies regarding the subject, all available studies on the topic were included in the present review.

## 2. Biological role of Zn in the retina

Zn is considered an integral component of Cu-Zn superoxide dismutase (SOD) enzyme which is a very important antioxidant defense system and protects the cells from the damages caused by free radicals (22). Zn ions are encountered in more than 300 enzymes and proteins, as well as in Zn finger transcription factors, immune function, and the metabolism of carbohydrates and proteins (5,6,9). It plays a fundamental role in conserving normal ocular function. It is present in high concentrations in the ocular tissue, particularly in the retina and the choroid (17). As demonstrated by PIXE and synchrotron XRF imaging, Zn is found at high levels in the retinal pigment epithelium (RPE)/choroid, photoreceptor inner segments (RIS)/outer limiting membrane (OLM) layer, outer plexiform layer (OPL), and inner nuclear layer (INL) (18,22). In the RPE, Zn is important in the antioxidant systems and the function of retinol dehydrogenase, an enzyme required in the visual cycle of retinol (10). In the plexiform layer, free Zn ions regulate the activity of the membrane receptors and channels at the level of bipolar and horizontal cells, while higher concentrations of Zn were also reported in the intracellular organelles of Muller cells involved in multiple metabolic functions (23-25). Morrison *et al* suggested that rods are more sensitive than cones to Zn deficiency, presenting 6 cases with Zn deficiency and nocturnal vision adaptation abnormalities, that responded favorably when treated with Zn supplements (26).

Low levels of Zn cause tissue and cellular damage, due to increased levels of free radicals. Prolonged Zn depletion induces retinal and EPR damages, and the involved pathological mechanisms include increased oxidative stress, lipofuscin accumulation in the RPE, and photoreceptor disruption (10,27).

In increased exposure to Zn, no retinal manifestations were described, probably due to the efficiency of homeostasis of retinal mechanisms. However, in experimental conditions, high Zn overload generated retinal toxicity, due to mitochondrial injury, apoptosis, and oxidative stress (18,28).

## 3. Zn metabolism disturbances in DM

Conversely, Zn is an essential trace element that is directly involved in the synthesis, storage, and release of insulin (29). It is present in secretory vesicles within  $\beta$ -cells of the pancreas

where it participates in the crystallization of insulin and is thus released alongside insulin into the plasma (30). Insulin homeostasis is disrupted by Zn deficiency, resulting in a decreased insulin secretion by  $\beta$ -cells (31). Zn supplementation has been revealed to improve insulin and glucose levels in diabetic subjects and decrease the risk of developing T2DM (32).

In a study conducted by Devi *et al*, Zn levels in diabetics, both with complications and without complications, were revealed to be lower than in the control group (33). Similar results were revealed in other studies (21,33-36).

Hyperglycemia and hyperinsulinemia increase the production of free radicals. Thus, the protection of Zn against free radicals generated in this chronic disease will be diminished (33).

A significant negative association between the duration of diabetes, fasting blood sugar, glycosylated hemoglobin levels of diabetic patients and their serum Zn levels has been revealed (34-36). Anderson *et al* reported that 30% of patients with DM were found to be Zn deficient (37). However, the exact mechanisms of Zn depletion in diabetes could not be established. Increased urinary excretion, decreased gastrointestinal absorption or a combination of both may explain Zn deficit in diabetics (38). Several studies indicated a significant correlation between increased zincuria and polyuria, due to increased urine volume, while others correlated Zn excretion with glycosuria and proteinuria (38-40).

#### 4. Biological role of Cu in the retina and optic nerve

Cu has bidirectional actions as an antioxidant and prooxidant, depending on the concentrations and tissue sensitivity. On the one hand, Cu is an essential element for the existence of life, important in several cellular mechanisms. Cu is part of the COX1 and COX2 subunits of the respiratory enzyme, cytochrome c oxidase, monoamine oxidase, SOD, tyrosinase, and ascorbic oxidase (41). Cu is an important antioxidant participating, along with Zn in the Cu-Zn SOD.

At the retinal level, higher Cu concentration was identified at the RPE/choroid and RIS/OLM. Previously, Cu was revealed to also be involved in neurotransmission at the level of the plexiform layer (19).

Cu deficiency is reported to cause neuropathy in general, but also decreased vision and optic nerve involvement (42-44). The signs and symptoms reported were decreased visual acuity, visual field changes, disturbances in color vision, optic atrophy, and retinal nerve fiber thinning, but with normal electroretinogram (ERG), suggesting normal retinal function. The pathogenic mechanism involves demyelination, and Cu supplementation may terminate, but not cure the damages (45-50).

By contrast, chronic increased free Cu levels, not bound by ceruloplasmin which acts as a potent antioxidant, may cause increased oxidative stress and ROS accumulation, with macromolecule injuries (46). In addition, free Cu ions are potent inhibitors of enzymes, induce cellular membrane and mitochondrial damages, and may generate optic nerve fiber lesions via glutamatergic NMDA311 and AMPA222 receptors and activation of nitric oxide synthetase (19). In an experimental study on rats, Civelek *et al* revealed that free Cu ions may favor glycation and lipid peroxidation (51).

Thus, an adequate balance of serum Cu levels should be maintained.

#### 5. Cu metabolism disturbances in diabetic patients

Numerous clinical studies have revealed that the high Cu levels are associated with several metabolic and inflammatory diseases (52-57). High Cu levels were revealed to be correlated with fatty liver, metabolic syndrome, and diabetes, possibly explained by the chronic low-grade inflammation and raised glycemic values. Insulin reduces Cu concentration in the liver through the regulation of at least one Cu-transporting ATPase, ATP7B (58). An accumulation of Cu in the liver may be due to decreased insulin levels (59).

Devi *et al* have revealed increased Cu levels in diabetic patients, both with complications and without complications when compared with the control group (33). A similar finding was observed by other previous studies (60-62). The increase in Cu ion levels in patients may be attributed to hyperglycemia that may stimulate glycation and release of Cu ions from Cu-binding sites of proteins (63). The release of Cu ions into the blood further accelerates oxidative stress. Cu in its free form is a potent cytotoxic element, due to its oxidative capacities (22). The main Cu-binding proteins in plasma are ceruloplasmin and serum albumin. Chronic hyperglycemia alters the Cu binding properties of both (64). Low Zn levels may also favor Cu toxicity, as Zn competes with Cu and iron in the cell membrane (65). Cu, bound to glycated proteins, may blunt normal endothelium-derived relaxing factor (EDRF)-dependent relaxation of diabetic arteries, and provide a rationale for the use of transition metal chelators in the therapy of diabetic vasculopathy and neuropathy (63,66).

#### 6. Serum Cu and Zn levels in DR vs. controls in clinical studies

Oxidant-antioxidant imbalance is the major cause of complications in diabetes, including DR. It is estimated that serum vitamin A and Zn levels may be decreased due to hyperglycemia which induces oxidative stress pathways (13). Zn is an inducer of gene and protein expression of metallothionein (MT), which is an effective antioxidant (67). Zn deficiency is associated with the progression of chronic disease states such as metabolic syndrome, diabetes, diabetic microvascular complications, and DR (6,66).

Several studies have documented the comparative serum levels of patients with DR (Table I). Although the findings revealed wide variations, there are similar conclusions. Zn levels were significantly decreased in patients with DR vs. T2DM without retinopathy and normal subjects. Additionally, Zn levels were negatively correlated with HbA1C and diabetes duration (68). Conversely, serum Cu was increased in DR, when compared with non-retinopathy diabetics and controls.

Zn protection in DR may be related to stabilizing the membrane structure, activating MT, decreased lipid peroxidation, and protecting pericytes. Zn has an anti-inflammatory effect, reducing the expression of VEGF which is related to inflammation in the ischemic retina, thus decreasing exudation and neovascularization (9). Zn deficiency causes decreased antioxidant protection and is associated with cellular and

Table I. Serum copper and zinc levels in diabetic retinopathy, type 2 diabetic patients without retinopathy and controls in clinical studies.

Study	Controls ( $\mu\text{g/dl}$ )	DM no retinopathy ( $\mu\text{g/dl}$ )	DM with retinopathy ( $\mu\text{g/dl}$ )
Mor <i>et al</i> (6)	Copper: 103 $\pm$ 7.08 Zinc: 67.6 $\pm$ 6.23	No information	Copper: 129 $\pm$ 14.3 Zinc: 54 $\pm$ 6.09
Luo <i>et al</i> (9)	No information	Zinc: 84.9 (41-137)	Zinc: 78.45 (52.3-183)
Ganiger <i>et al</i> (66)	Copper: 106.4 $\pm$ 19.03 Zinc: 90.16 $\pm$ 19.4	Copper: 166.3 $\pm$ 24.35 Zinc: 67.50 $\pm$ 13.85	Copper: 238.1 $\pm$ 27.39 Zinc: 50.5 $\pm$ 11.9
Rostamkhani <i>et al</i> (70)	Zinc: 70.1 $\pm$ 2.7	No information	Zinc: 66.2 $\pm$ 2.4 (NPDR) 60.9 $\pm$ 2.5 (PDR)

DM, diabetes mellitus; DR, diabetic retinopathy; NPDR, non-proliferative DR; PDR, proliferative DR.

tissue damage at the retinal level. As Zn and Cu homeostasis are closely linked, notably, through competition during intestinal absorption and through shared transporter proteins such as serum albumin, a deficiency in one can affect the other (69).

Impaired metabolism of Zn and Cu are associated with higher sensitivity to oxidative damage, as both Zn and Cu are required for the activity of the antioxidant enzyme SOD, whose activity is reduced. In lower serum levels of vitamin A and Zn, the risk of DR and its severity increases (70).

## 7. Future therapeutic implications

Although tight glycemic control and preventing the additional risk factors, such as increased blood pressure and dyslipidemia remain the main therapeutic targets in the prevention of initiation and progression of DR, antioxidants may be a suitable choice for inhibiting intrinsic changes within the retinal capillary that lead to the development of DR. Close interdisciplinary follow-up of diabetic patients is essential to prevent progression to life-threatening complications. Diabetic patients were a neglected vulnerable group during the early phase of the COVID-19 pandemic. Furthermore, epidemiological studies evidenced that diabetes and obesity are among the main risk factors for death in Sars-Cov-2 infections (71-74). Several studies have revealed the beneficial role of Zn supplements on oxidative pathways in diabetes, by multiple beneficial effects including antioxidative effects, particularly in protecting sulfhydryl (SH) groups, but also through the modulating effect of Zn on insulin sensitivity (7,69,75-77).

Zn supplementation is effective to control the progression of DR, according to Naghizadeh *et al* (77). Rostamkhani *et al* (70) have revealed that an increase in serum Zn and vitamin A levels reduced the risk of DR by 25.7 and 31.1%, respectively. The antioxidants may be a suitable choice for inhibiting intrinsic changes within the retinal capillary that could lead to the development of DR (70). Supplements with Zn at a dose of 30 mg/day were revealed to decrease lipid peroxidation and improve antioxidant mechanisms in DM (75).

Diabetes is a cause of delayed wound healing following surgery and abnormal inflammatory response, due to multiple altered metabolic pathways. Senapati *et al* found a significant correlation between low Zn levels and wound complications

following surgery (78). Catabolism and surgical aggression are known to cause hyperzincuria in the following days after surgical intervention (79). Zn supplementation was revealed to be beneficial following surgical interventions even in non-diabetic patients (79,80). Correction of serum Zn levels may be considered preoperatively, to minimize complications in safe surgery management of diabetic patients (80). However, Zn over-supplementation can lead to Cu deficiency, as suggested by Duncan *et al*, due to competitive mechanisms of gastrointestinal absorption (80).

Selective divalent Cu chelation in increased Cu levels may be a possible therapeutic approach targeting these Cu-mediated pathogenic mechanisms, which suppresses Cu-mediated oxidative stress and restores antioxidant defenses (6,81).

## 8. Conclusions

Trace elements are recognized as important substances for human health due to their metabolic characteristics and functions. Lower Zn status accompanied by increased Cu levels were reported in patients with DR. Disturbances in serum levels of Cu and Zn may play a significant role in the onset and progression of DR, particularly due to increased oxidative stress. Zn supplementation and Cu chelation may help to reduce the complications of DM. However, further studies on larger study groups are required to confirm these findings.

## Acknowledgements

Not applicable.

## Funding

No funding was received.

## Availability of data and materials

Not applicable.

## Authors' contributions

AMD, AAD, DStA, LCT and DrS contributed to the conception and design of this study. AMD, DSer and AAD performed the

literature research. VAN, ACC, DOC, MST, LCT, AZ, MT, CT and LD were responsible for the data collection and analysis. AMD, AAD, SAB, VAN, ACC and DaS were in charge of drafting the manuscript. MST, SAB, LD, DOC, MT, CT, DSer and DT revised the manuscript critically for important intellectual content. The final version was read and approved by all authors. Data authentication is not applicable.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

- Liu J, Ren ZH, Qiang H, Wu J, Shen M, Zhang L and Lyu J: Trends in the incidence of diabetes mellitus: Results from the global burden of disease study 2017 and implications for diabetes mellitus prevention. *BMC Public Health* 20: 1415, 2020.
- Pop A, Clenciu D, Anghel M, Radu S, Socea B, Mota E, Mota M and Panduru NM; RomDiane Study Group: Insulin resistance is associated with all chronic complications in type 1 diabetes. *J Diabetes* 8: 220-228, 2016.
- Fowler MJ: Microvascular and macrovascular complications of diabetes. *Clin Diabetes* 26: 77-82, 2008.
- Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S and Chalmers J: Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. *Cardiovasc Diabetol* 16: 95, 2017.
- Chawla A, Chawla R and Jaggi S: Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? *Indian J Endocrinol Metab* 20: 546-551, 2016.
- Mor P, Rathore AR, Sonagra V, Sharma N and Sharma A: A study of serum copper, zinc and magnesium in type 2 diabetes mellitus with complications and without complications. *Biomed Pharmacol J* 13: 1927-1930, 2020.
- Hasanato RM: Trace elements in type 2 diabetes mellitus and their association with glycemic control. *Afr Health Sci* 20: 287-293, 2020.
- Salgueiro MJ, Krebs N, Zubillaga MB, Weill R, Postaire E, Lysionek AE, Caro RA, De Paoli T, Hager A and Boccio J: Zinc and diabetes mellitus: Is there a need of zinc supplementation in diabetes mellitus patients? *Biol Trace Elem Res* 81: 215-228, 2001.
- Luo YY, Zhao J, Han XY, Zhou XH, Wu J and Ji LN: Relationship between serum zinc level and microvascular complications in patients with type 2 diabetes. *Chin Med J (Engl)* 128: 3276-3282, 2015.
- Miao X, Sun W, Miao L, Fu Y, Wang Y, Su G and Liu Q: Zinc and diabetic retinopathy. *J Diabetes Res* 2013: 425854, 2013.
- Tudosie MS, Miulescu RD, Negulescu V, Ionica M, Stefan DS, Corlan G and Macovei R: Evaluation and modeling of pharmacokinetics of copper ion during hemodialysis. *Farmacia* 61: 53-65, 2013.
- Lee SR: Critical role of zinc as either an antioxidant or a prooxidant in cellular systems. *Oxid Med Cell Longev* 2018: 9156285, 2018.
- Giacco F and Brownlee M: Oxidative stress and diabetic complications. *Circ Res* 107: 1058-1070, 2010.
- Lee R, Wong TY and Sabanayagam C: Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis (Lond)* 2: 17, 2015.
- Zugravu CA, Baciuc A, Patrascu D, Tarcea M and Pantea Stoian A: Depression and diabetes: Are there any consequences on self-care? *Eur J Public Health* 22: 272, 2012.
- Stoian AP, Mitrofan G, Colceag F, Suceveanu AI, Hainarosi R, Pituru S, Diaconu CC, Timofte D, Nitipir C, Poiana C and Serafinceanu C: Oxidative stress in diabetes a model of complex thinking applied in medicine. *Rev Chim* 69: 2515-2519, 2018.
- Serban D, Papanas N, Dascalu AM, Stana D, Nicolae VA, Vancea G, Badiu CD, Tanasescu D, Tudor C, Balasescu SA and Pantea-Stoian A: diabetic retinopathy in patients with diabetic foot ulcer: A systematic review. *Int J Low Extrem Wounds* 20: 98-103, 2021.
- Cheung N, Mitchell P and Wong TY: Diabetic retinopathy. *Lancet* 376: 124-136, 2010.
- Ugarte M, Osborne NN, Brown LA and Bishop PN: Iron, zinc, and copper in retinal physiology and disease. *Surv Ophthalmol* 58: 585-609, 2013.
- Kang JH, Pasquale LR, Willett WC, Rosner BA, Egan KM, Faberowski N and Hankinson SE: Dietary fat consumption and primary open-angle glaucoma. *Am J Clin Nutr* 79: 755-764, 2004.
- Anetor JI, Senjobi A, Ajose OA and Agbedana EO: Decreased serum magnesium and zinc levels: Atherogenic implications in type-2 diabetes mellitus in Nigerians. *Nutr Health* 16: 291-300, 2002.
- Kumar DA, Priya VS, Jaiprabhu J and Ramalingam K: Serum copper and zinc levels significance in type 2 diabetic patients. *J Med Sci Tech* 3: 79-81, 2014.
- Ugarte M and Osborne NN: Zinc in the retina. *Prog Neurobiol* 64: 219-249, 2001.
- Li Y, Anderegg L, Yuki K, Omura K, Yin Y, Gilbert HY, Erdogan B, Asdourian MS, Shrock C, de Lima S, *et al*: Mobile zinc increases rapidly in the retina after optic nerve injury and regulates ganglion cell survival and optic nerve regeneration. *Proc Natl Acad Sci USA* 114: E209-E218, 2017.
- Redenti S and Chappell RL: Müller cell zinc transporter-3 labeling suggests a role in outer retina zinc homeostasis. *Mol Med* 13: 376-379, 2007.
- Morrison SA, Russell RM, Carney EA and Oaks EV: Zinc deficiency: A cause of abnormal dark adaptation in cirrhotics. *Am J Clin Nutr* 31: 276-281, 1978.
- Brunk UT, Wihlmark U, Wrigstad A, Roberg K and Nilsson SE: Accumulation of lipofuscin within retinal pigment epithelial cells results in enhanced sensitivity to photo-oxidation. *Gerontology* 41 (Suppl 2): S201-S212, 1995.
- Nita M and Grzybowski A: The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. *Oxid Med Cell Longev* 2016: 3164734, 2016.
- Yahya H, Yahya KM and Saqib A: Minerals and type 2 diabetes mellitus-level of zinc, magnesium and chromium in diabetic and non diabetic population. *JUMDC* 2: 34-38, 2011.
- Praveena S, Pasula S and Sameera K: Trace elements in diabetes mellitus. *J Clin Diagn Res* 7: 1863-1865, 2013.
- Fung EB, Gildengorin G, Talwar S, Hagar L and Lal A: Zinc status affects glucose homeostasis and insulin secretion in patients with thalassemia. *Nutrients* 7: 4296-4307, 2015.
- Ranasinghe P, Wathurapatha WS, Galappathya P, Katulanda P, Jayawardena R and Constantine GR: Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial. *J Diabetes* 10: 386-397, 2018.
- Devi TR, Hijam D, Dubey A, Debnath S, Oinam P, Devi NT and Singh W: Study of Serum Zinc and Copper levels in Type 2 Diabetes Mellitus. *Int J Contemp Med Res* 3: 1036-1040, 2016.
- Al-Marouf RA and Al-Sharbatti SS: Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics: *Saudi Med J* 27: 344-350, 2006.
- Walter RM Jr, Uriu-Hare JY, Olin KL, Oster MH, Anawalt BD, Critchfield JW and Keen CL: Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. *Diabetes Care* 14: 1050-1056, 1991.
- Saharia GK and Goswami RK: Evaluation of serum zinc status and glycated hemoglobin of type 2 diabetes mellitus patients in a tertiary care hospital of assam. *J Lab Physicians* 5: 30-33, 2013.
- Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM and Kerkeni A: Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. *J Am Coll Nutr* 20: 212-218, 2001.
- Jansen J, Karges W and Rink L: Zinc and diabetes-clinical links and molecular mechanisms. *J Nutr Biochem* 20: 399-417, 2009.
- Brun JF, Fons C, Fussellier M, Bardet L and Orsetti A: Urinary zinc and its relationships with microalbuminuria in type I diabetics. *Biol Trace Elem Res* 32: 317-323, 1992.

40. Poudel RR, Bhusal Y, Tharu B and Kafle NK: Role of zinc in insulin regulation and diabetes. *J Soc Health Diabetes* 5: 83-87, 2017.
41. Tudosie MS, Truta E, Davitoiu AM, Stanciulescu L, Jinescu G, Mitu AM, Forje M, Horhota L, Bojescu AA, Mares AM and Ionica M: The impact of copper in children with attention deficit hyperactivity disorder. *Rev Chim* 68: 279-283, 2017.
42. Naismith RT, Shepherd JB, Weihi CC, Tutlam NT and Cross AH: Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. *Arch Neurol* 66: 1025-1027, 2019.
43. Jaiser SR and Winston GP: Copper deficiency myelopathy. *J Neurol* 257: 869-881, 2010.
44. Shah AR and Tamhankar MA: Optic neuropathy associated with copper deficiency after gastric bypass surgery. *Retin Cases Brief Rep* 8: 73-76, 2014.
45. Klevay LM: Ocular lesions from copper deficiency. *Indian J Med Res* 146: 430-431, 2017.
46. Gregg XT, Reddy V and Prchal JT: Copper deficiency masquerading as myelodysplastic syndrome. *Blood* 100: 1493-1495, 2002.
47. Spinazzi M, De Lazzari F, Tavolato B, Angelini C, Manara R and Armani M: Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. Do small bowel bacterial overgrowth syndrome and occult zinc ingestion tip the balance? *J Neurol* 254: 1012-1017, 2007.
48. Rapoport Y and Lavin PJ: Nutritional optic neuropathy caused by copper deficiency after bariatric surgery. *J Neuroophthalmol* 36: 178-181, 2016.
49. Pineles SL, Wilson CA, Balcer LJ, Slater R and Galetta SL: Combined optic neuropathy and myelopathy secondary to copper deficiency. *Surv Ophthalmol* 55: 386-392, 2010.
50. Dake Y and Amemiya T: Electron microscopic study of the optic nerve in copper deficient rats. *Exp Eye Res* 52: 277-281, 1991.
51. Civelek S, Gelişen R, Andican G, Seven A, Küçük SH, Özdoğan M and Burçak G: Advanced glycation end products and antioxidant status in nondiabetic and streptozotocin induced diabetic rats: Effects of copper treatment. *Biometals* 23: 43-49, 2010.
52. Balsano C, Porcu C and Sideri S: Is copper a new target to counteract the progression of chronic diseases? *Metallomics* 10: 1712-1722, 2018.
53. Aigner E, Weiss G and Datz C: Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver. *World J Hepatol* 7: 177-188, 2015.
54. Lowe J, Taveira-da-Silva R and Hilário-Souza E: Dissecting copper homeostasis in diabetes mellitus. *IUBMB Life* 69: 255-262, 2017.
55. Arciello M, Longo A, Viscomi C, Capo C, Angeloni A, Rossi L and Balsano C: Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload. *Biometals* 28: 1017-1029, 2015.
56. Jung UJ and Choi MS: Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. *Int J Mol Sci* 15: 6184-6223, 2011.
57. Zhang S, Liu H, Amarsingh GV, Cheung CC, Hogg S, Narayanan U, Zhang L, McHarg S, Xu J, Gong D, *et al*: Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation. *Cardiovasc Diabetol* 13: 100, 2014.
58. Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-Schönauer U, Steindl-Munda P, Stadlmayr A, Wrba F, Trauner M, Datz C and Ferenci P: Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. *J Trace Elem Med Biol* 39: 100-107, 2017.
59. Peng KY, Watt MJ, Rensen S, Greve JW, Huynh K, Jayawardana KS, Meikle PJ and Meex RC: Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression. *J Lipid Res* 59: 1977-1986, 2018.
60. Hilário-Souza E, Cuillel M, Mintz E, Charbonnier P, Vieyra A, Cassio D and Lowe J: Modulation of hepatic copper-ATPase activity by insulin and glucagon involves protein kinase A (PKA) signaling pathway. *Biochim Biophys Acta* 1862: 2086-2097, 2016.
61. Di-Silvestro RA: Zinc in relation to diabetes and oxidative disease. *J Nutr* 130 (Suppl 5): 1509S-1511S, 2000.
62. Zarga AH, Shah NA, Masoodi SR, Laway BA, Dar FA, Khan AR, Sofi FA and Wani AI: Copper, zinc, and magnesium levels in non-insulin dependent diabetes mellitus. *Postgrad Med J* 74: 665-668, 1998.
63. Eaton JW and Qian M: Interactions of copper with glycosylated proteins: Possible involvement in the etiology of diabetic neuropathy. *Mol Cell Biochem* 234-235: 135-142, 2002.
64. Argirova MD and Ortwerth BJ: Activation of protein-bound copper ions during early glycation: Study on two proteins. *Arch Biochem Biophys* 420: 176-184, 2003.
65. Cruz KJ, de Oliveira AR and Marreiro Ddo N: Antioxidant role of zinc in diabetes mellitus. *World J Diabetes* 6: 333-337, 2015.
66. Ganiger A, Swamy MK, Shankar Prasad DS, Mannangi NB and Gundalli S: Study of serum copper and zinc in diabetic retinopathy and its correlation with glycemic status. *Int J Clin Biochem Res* 3: 76-81, 2016.
67. Rodríguez-Menéndez S, García M, Fernández B, Álvarez L, Fernández-Vega-Cueto A, Coca-Prados M, Pereiro R and González-Iglesias H: The zinc-metallothionein redox system reduces oxidative stress in retinal pigment epithelial cells. *Nutrients* 10: 1874, 2018.
68. Farooq DM, Alamri AF, Alwhahabi BK, Metwally AM and Kareem KA: The status of zinc in type 2 diabetic patients and its association with glycemic control. *J Family Community Med* 27: 29-36, 2020.
69. Osredkar J and Sustar N: Copper and zinc, biological role and significance of copper/zinc imbalance. *J Clin Toxicol* S3: 001-018, 2011.
70. Rostamkhani H, Mellati AA, Tabaei BS, Alavi M and Mousavi SN: Association of serum zinc and vitamin A levels with severity of retinopathy in type 2 diabetic patients: A cross-sectional study. *Biol Trace Elem Res* 192: 123-128, 2019.
71. Pantea Stoian A, Pricop-Jeckstadt M, Pana A, Ileanu BV, Schitea R, Geanta M, Catrinioiu D, Suceveanu AI, Serafinceanu C, Pituru S, *et al*: Death by SARS-CoV 2: A Romanian COVID-19 multi-centre comorbidity study. *Sci Rep* 10: 21613, 2020.
72. Hui Y, Li Y, Tong X, Wang Z, Mao X, Huang L and Zhang D: The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan. *PLoS One* 15: e0243602, 2020.
73. Stoian AP, Papanas N, Prazny M, Rizvi AA and Rizzo M: Incretin-based therapies role in COVID-19 era: Evolving insights. *J Cardiovasc Pharmacol Ther* 25: 494-496, 2020.
74. Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, Denaxas S, McGovern AP and Vollmer SJ: Type 2 diabetes and COVID-19-related mortality in the critical care setting: A national cohort study in England, March-July 2020. *Diabetes Care* 44: 50-57, 2021.
75. Roussel AM, Kerkeni A, Zouari N, Mahjoub S, Matheau JM and Anderson RA: Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. *J Am Coll Nutr* 22: 316-321, 2003.
76. Mousavi SN, Faghihi A, Motaghinejad M, Shiasi M, Imanparast F, Amiri HL and Shidfar F: Zinc and selenium co-supplementation reduces some lipid peroxidation and angiogenesis markers in a rat model of NAFLD-fed high fat diet. *Biol Trace Elem Res* 181: 288-295, 2018.
77. Naghizadeh S, Kheirouri S, Ojaghi H and Jafari Kaffash A: Zinc supplementation attenuate diabetic indices in patients with diabetic retinopathy. *Progr Nutr* 20 (Suppl 2): S263-S269, 2018.
78. Senapati A, Slavin BM and Thompson RP: Zinc depletion and complications of surgery. *Clin Nutr* 9: 341-346, 1990.
79. Adjepong D, Jahangir S and Malik B: The effect of zinc on post-neurosurgical wound healing: A review. *Cureus* 12: e6770, 2020.
80. Duncan A, Yacoubian C, Watson N and Morrison I: The risk of copper deficiency in patients prescribed zinc supplements. *J Clin Pathol* 68: 723-725, 2015.
81. Cooper GJ: Selective divalent copper chelation for the treatment of diabetes mellitus. *Curr Med Chem* 19: 2828-2860, 2012.